Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

12.59USD
1 Aug 2014
Price Change (% chg)

$-0.19 (-1.49%)
Prev Close
$12.78
Open
$12.71
Day's High
$12.74
Day's Low
$12.45
Volume
1,955,168
Avg. Vol
2,482,138
52-wk High
$14.07
52-wk Low
$10.54

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions,... (more)

Overall

Beta: 1.09
Market Cap (Mil.): $16,903.79
Shares Outstanding (Mil.): 1,322.68
Dividend: --
Yield (%): --

Financials

Search Stocks

Boston Scientific wins first trial over transvaginal mesh device

- A Massachusetts jury has cleared Boston Scientific Corp of selling dangerous and defective transvaginal mesh devices, in the first out of more than 20,000 lawsuits waiting to go to trial.

30 Jul 2014

Boston Scientific wins first trial over transvaginal mesh device

July 30 - A Massachusetts jury has cleared Boston Scientific Corp of selling dangerous and defective transvaginal mesh devices, in the first out of more than 20,000 lawsuits waiting to go to trial.

30 Jul 2014

UPDATE 2-Boston Scientific profit exceeds expectations as sales rise

July 24 - Boston Scientific Corp, which makes medical equipment, on Thursday reported a slightly higher-than-expected quarterly profit as improvements in its heart device business helped drive revenue up 4 percent.

24 Jul 2014

Boston Scientific reports profit as sales rise

July 24 - Boston Scientific, which makes medical equipment, on Thursday reported a better-than-expected profit as sales across all sectors including its large heart device business improved by 4 percent on a constant currency basis.

24 Jul 2014

Fitch Affirms Boston Scientific's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, July 09 (Fitch) Fitch Ratings has affirmed Boston Scientific Corp.'s (NYSE: BSX) long-term IDR at 'BBB-' with a Stable Outlook. A full list of BSX's ratings follows at the end of this release. The rating action applies to approximately $4.25 billion of debt. KEY RATING DRIVERS: --Fitch expects BSX will operate with relatively stable leverage (total debt/EBITDA) of 2.3x-2.5x during the next 12 months, despite a challenging

09 Jul 2014

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, June 17,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Res

17 Jun 2014

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, June 16,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Res

16 Jun 2014

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, June 13,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Res

13 Jun 2014

UPDATE 1-Boston Scientific buys Bayer's vascular catheter business

* Unit makes catheters to remove clots from arteries and veins

15 May 2014

Bayer sells Interventional device unit to Boston Scientific

FRANKFURT - Bayer AG on Thursday said it agreed to sell its Interventional device business to Boston Scientific for $415 million in cash, a deal that is expected to close in the second half of 2014.

15 May 2014

Competitors

  Price Change
Abbott Laboratories (ABT.N) $42.03 -0.09
Medtronic, Inc. (MDT.N) $61.48 -0.26
St. Jude Medical, Inc. (STJ.N) $65.24 +0.05

Earnings vs. Estimates

Search Stocks